A share price of Pliant Therapeutics Inc [PLRX] is currently trading at $1.8, up 7.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PLRX shares have gain 9.76% over the last week, with a monthly amount glided 19.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pliant Therapeutics Inc [NASDAQ: PLRX] stock has seen the most recent analyst activity on October 10, 2025, when JP Morgan downgraded its rating to a Underweight. On March 04, 2025, downgrade downgraded it’s rating to Hold. Stifel downgraded its rating to a Hold. Leerink Partners downgraded its rating to a Market Perform. Wells Fargo downgraded its rating to Equal Weight for this stock on February 10, 2025, and downed its price target to $4. In a note dated February 10, 2025, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $45 to $4.
Pliant Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.10 and $15.80. Currently, Wall Street analysts expect the stock to reach $31.14 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $1.8 at the most recent close of the market. An investor can expect a potential return of 1630.0% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
Gross Profit Margin for this corporation currently stands at 0.11% with Operating Profit Margin at -81.99%, Pretax Profit Margin comes in at -77.31%, and Net Profit Margin reading is -77.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.72 and Total Capital is -0.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7083 points at the first support level, and at 1.6167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8533, and for the 2nd resistance point, it is at 1.9067.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pliant Therapeutics Inc [NASDAQ:PLRX] is 13.93. As well, the Quick Ratio is 13.93, while the Cash Ratio is 5.32.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jan 17 ’25 when 52419.0 shares were sold. Chief Financial Officer, Cummings Keith Lamont completed a deal on Jan 17 ’25 to sell 20148.0 shares. Meanwhile, Chief Business Officer Hull Hans sold 15936.0 shares on Jan 17 ’25.
